A groundbreaking study from Adelaide University has cast a critical eye on the ingredient salcaprozate sodium (SNAC), commonly used in tablet forms of weight-loss medications. The research indicates that SNAC, which enhances absorption, may have significant biological effects on the gut and beyond.
This study is the first of its kind to systematically assess the impact of repeated SNAC exposure on gut microbiota composition, function, and metabolic outcomes. Conducted over 21 days using an animal model, the researchers observed several concerning changes:
- Decreased levels of beneficial gut bacteria essential for breaking down dietary fiber.
- Reduced short-chain fatty acids, which are crucial for gut lining protection and inflammation regulation.
- Elevated blood inflammatory markers.
- Increased liver weight, potentially signaling low-grade inflammation.
- A smaller caecum, the intestinal area where gut bacteria break down fiber and produce protective compounds.
- Lower levels of a brain-derived protein linked to cognitive impairment.
While the study does not conclusively demonstrate that SNAC is harmful, the findings suggest that the absorption enhancer may have biological effects beyond its role in facilitating semaglutide absorption in pill form.
Understanding SNAC’s Role in Weight-Loss Medications
Semaglutide, the active ingredient in popular weight-loss drugs, is traditionally administered via injection, allowing it to enter the bloodstream directly. In its tablet form, SNAC plays a crucial role by protecting semaglutide from enzymatic degradation in the stomach, enabling its absorption. Without SNAC, oral semaglutide would be ineffective.
The recent approval of the Wegovy tablet in the United States has heightened interest in SNAC, as the tablet is expected to offer a more convenient and cost-effective alternative to injections. Consequently, long-term daily exposure to SNAC is anticipated to rise significantly.
Global Obesity: A Growing Concern
Globally, obesity affects approximately 890 million people, including 160 million children, equating to one in eight individuals worldwide. The United States leads OECD countries with an obesity rate of 43% among those aged 15 and older, while Australia ranks sixth at 31%, surpassing the OECD average of 25%.
In Australia, prescriptions for weight-loss medications such as Ozempic and Wegovy have surged in recent years. This trend underscores the importance of understanding the full biological impact of SNAC to mitigate any potential long-term health effects.
Expert Insights and Future Directions
Lead author and Adelaide University PhD candidate Amin Ariaee emphasizes the urgency of comprehensively understanding SNAC’s biological impact, given the rapid growth in oral obesity treatments utilizing this ingredient.
“Obesity is a complex, chronic disease with serious health consequences. These medicines are highly effective and are helping many people,” Ariaee says. “But as oral versions become more widely used, we need to understand what repeated, long-term exposure to all ingredients in the pill means for the body – not just the active drug.”
Senior Research Fellow Dr. Paul Joyce advises caution, noting that these findings are preliminary and derived from animal models, not human subjects. He stresses the need for further research to bridge this significant gap in understanding.
“Importantly, our findings do not prove that SNAC causes harm in humans,” Dr. Joyce states. “However, they do show that the ingredient enabling these tablets to work may have adverse biological effects beyond drug absorption.”
The implications of these findings are significant, as these medications are typically taken daily and often for extended periods. As their use expands globally, it becomes increasingly important to evaluate all components of these therapies, not just the active compound.
With the potential for SNAC to impact gut health and beyond, further investigation is warranted to ensure the safety and efficacy of oral weight-loss treatments. As research continues, the medical community and consumers alike will be watching closely for developments that could influence the future of obesity management.
